STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity

Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response re...

Full description

Bibliographic Details
Main Authors: Matteo Rossi, Susanna Carboni, Wilma Di Berardino-Besson, Erika Riva, Marie-Laure Santiago-Raber, Elodie Belnoue, Madiha Derouazi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
STING agonist
protein cancer vaccine
combination immunotherapy
CD8 T cells functionality
Th1 CD4 T cells
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.695056/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.695056/full

Similar Items